slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 39,631-39,660
Pages 2,019
Rows per page 30
Component
39,631-39,660 of 60,557
29
The slide uses a table for disease phenotypes and a vertical timeline for the COVID-19 study milestones.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
32
The slide displays a grid of heatmaps/data tables for different medical categories, with a specific example for NAFLD at the bottom.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
51
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
52
Fiscal year ends March 31.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
53
Includes a callout highlighting the growth in Therapeutics R&D investment.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
54
Balances may not add up due to rounding.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
05
The table uses a waterfall-style logic to explain the variance between two periods.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
16
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
17
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
18
The table includes a footnote clarifying the adjusted basis for specific segments.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
05
The chart combines a line graph (investment/risk profile) with a bar chart (revenue/sales) over a 21-year timeline.AbCellera | Investor Conference Presentation Deck | 19 slides · AbCellera
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
21
The slide uses a table-like layout to present key company metrics as evidence of market readiness.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · ActionLoop · Before After1 hit
04
The slide uses a Gantt-style chart to represent clinical trial progress.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
20
Clinical trial safety data comparing Pegzilarginase to Placebo.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
25
Includes a Kaplan-Meier survival curve and a comparative table of clinical outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
29
Data presented includes age, sex, and region for a total N=32.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
30
The table displays mean/SD and median/range for Plasma Arginine, GMFM-E, and 2MWT, and counts/percentages for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
32
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
33
Includes a study design timeline and MCID reference lines for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
36
The table highlights specific clinical response metrics for six individual patients, demonstrating improvements and normalization of mobility scores.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
06
Includes a highlighted column for Q1'23 and detailed footnotes regarding product licensing and arbitration.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
07
The slide includes a disclaimer regarding the date of the expectations and a note about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
19
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Action1 hit
20
The table reconciles GAAP net loss of $180M to non-GAAP net income of $20M using various non-cash and one-time adjustments.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Action1 hit
18
The slide details the vesting logic for executive compensation based on absolute and relative performance metrics.UBS | Shareholder Engagement Presentation Deck | 21 slides · UBS
Shareholder letter Investor relations 1 hit
13
Includes a disclaimer regarding non-GAAP financial measures.Vivid Seats | Results Presentation Deck | 23 slides · Vivid Seats
Conference presentation Investor relations Beat · FinancialsLoop · Why Now1 hit
21
The table includes footnotes (1-9) referenced in the row labels.Vivid Seats | Results Presentation Deck | 23 slides · Vivid Seats
Conference presentation Investor relations 1 hit
22
The table provides a detailed breakdown of various adjustments (tax, interest, D&A, etc.) to arrive at Adjusted EBITDA margin.Vivid Seats | Results Presentation Deck | 23 slides · Vivid Seats
Conference presentation Investor relations 1 hit
17
The slide provides a detailed breakdown of adjustments including share-based compensation, amortization, and investment revaluations.Yatsen | Results Presentation Deck | 19 slides · Yatsen
Conference presentation Investor relations Beat · Visualization1 hit